408 related articles for article (PubMed ID: 37455828)
1. Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
Jou E
Explor Target Antitumor Ther; 2023; 4(3):474-497. PubMed ID: 37455828
[TBL] [Abstract][Full Text] [Related]
2. Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy.
Verner JM; Arbuthnott HF; Ramachandran R; Bharadwaj M; Chaudhury N; Jou E
Explor Target Antitumor Ther; 2024; 5(2):296-315. PubMed ID: 38745765
[TBL] [Abstract][Full Text] [Related]
3. Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis.
Jou E; Rodriguez-Rodriguez N; McKenzie ANJ
Front Immunol; 2022; 13():981479. PubMed ID: 36263033
[TBL] [Abstract][Full Text] [Related]
4. Saga of monokines in shaping tumour-immune microenvironment: Origin to execution.
Challagundla N; Shah D; Yadav S; Agrawal-Rajput R
Cytokine; 2022 Sep; 157():155948. PubMed ID: 35764025
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
6. Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia.
Klein B; Haggeney T; Fietz D; Indumathy S; Loveland KL; Hedger M; Kliesch S; Weidner W; Bergmann M; Schuppe HC
Hum Reprod; 2016 Oct; 31(10):2192-202. PubMed ID: 27609978
[TBL] [Abstract][Full Text] [Related]
7. Dominant expansion of CD4+, CD8+ T and NK cells expressing Th1/Tc1/Type 1 cytokines in culture-positive lymph node tuberculosis.
Kathamuthu GR; Sridhar R; Baskaran D; Babu S
PLoS One; 2022; 17(5):e0269109. PubMed ID: 35617254
[TBL] [Abstract][Full Text] [Related]
8. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
Zhou T; Damsky W; Weizman OE; McGeary MK; Hartmann KP; Rosen CE; Fischer S; Jackson R; Flavell RA; Wang J; Sanmamed MF; Bosenberg MW; Ring AM
Nature; 2020 Jul; 583(7817):609-614. PubMed ID: 32581358
[TBL] [Abstract][Full Text] [Related]
9. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
10. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
11. Role of interferons and other cytokines in the regulation of the immune response.
Belardelli F
APMIS; 1995 Mar; 103(3):161-79. PubMed ID: 7538771
[TBL] [Abstract][Full Text] [Related]
12. Cytokine networking of innate immunity cells: a potential target of therapy.
Striz I; Brabcova E; Kolesar L; Sekerkova A
Clin Sci (Lond); 2014 May; 126(9):593-612. PubMed ID: 24450743
[TBL] [Abstract][Full Text] [Related]
13. Stat6 activity-related Th2 cytokine profile and tumor growth advantage of human colorectal cancer cells in vitro and in vivo.
Li BH; Xu SB; Li F; Zou XG; Saimaiti A; Simayi D; Wang YH; Zhang Y; Yuan J; Zhang WJ
Cell Signal; 2012 Mar; 24(3):718-25. PubMed ID: 22108090
[TBL] [Abstract][Full Text] [Related]
14. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
16. Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses.
Gurram RK; Zhu J
Cell Mol Immunol; 2019 Mar; 16(3):225-235. PubMed ID: 30792500
[TBL] [Abstract][Full Text] [Related]
17. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
18. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
[TBL] [Abstract][Full Text] [Related]
19. Expression of bone-resorptive and regulatory cytokines in murine periapical inflammation.
Kawashima N; Stashenko P
Arch Oral Biol; 1999 Jan; 44(1):55-66. PubMed ID: 10075151
[TBL] [Abstract][Full Text] [Related]
20. Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight.
Andreone S; Gambardella AR; Mancini J; Loffredo S; Marcella S; La Sorsa V; Varricchi G; Schiavoni G; Mattei F
Front Immunol; 2020; 11():571593. PubMed ID: 33329534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
